



August 12, 2025

Listing Department
BSE LIMITED
P J Towers, Dalal Street,
Mumbai-400 001

Code: 532321

Listing Department
NATIONAL STOCK EXCHANGE OF INDIA LIMITED
Exchange Plaza, C/1, Block G,
Bandra Kurla Complex,
Bandra (E),
Mumbai-400 051

Code: ZYDUSLIFE

Sub: **Press Release**

Ref.: **Disclosure under regulation 30 of SEBI (Listing Regulations and Disclosure Requirements) Regulations, 2015 ("the Listing Regulations")**

Pursuant to the provisions of regulation 30 of the Listing Regulations, please find enclosed the press release dated August 12, 2025, to be published in the newspapers relating to unaudited financial results for the quarter ended on June 30, 2025.

Please find the same in order.

Yours faithfully,
For, **ZYDUS LIFESCIENCES LIMITED**

DHAVAL N. SONI
COMPANY SECRETARY AND COMPLIANCE OFFICER
MEMBERSHIP NO. FCS7063

Encl.: As above

Zydus Lifesciences Limited

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle,
S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878



Zydus Lifesciences Limited

Financial Performance for Q1 FY26

12th August, 2025, Ahmedabad, India

Zydus Lifesciences Limited announced its unaudited consolidated financial results for the first quarter ended June 30th, 2025.

Q1 FY26 Key Financial Highlights

- Revenue from Operations was Rs. 65,737 mn, up 6% YoY.
- Research & Development (R&D) investments for the quarter stood at Rs. 4,856 mn (7.4% of revenues).
- EBITDA for the quarter was Rs. 20,885 mn, flat YoY. EBITDA margin for the quarter stood at 31.8%.
- Net Profit for the quarter was Rs. 14,668 mn, up 3% YoY.
- Capex (organic) for the quarter was Rs. 4,020 mn.

Q1 FY26 Consolidated Financial Results

Rs. mn	Q1 FY26	Q1 FY25	% Gr. YoY	Q4 FY25	% Gr. QoQ
Revenue from operations	65,737	62,075	5.9%	65,279	0.7%
EBITDA	20,885	20,840	0.2%	21,255	-1.7%
EBITDA margin (%)	31.8%	33.6%		32.6%	
PBT	19,206	18,997	1.1%	16,720	14.9%
Net Profit	14,668	14,199	3.3%	11,709	25.3%

Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878






Dedicated To Life

Q1 FY26 Business-wise Sales Performance (Consolidated)

Rs. mn	Q1 FY26	Q1 FY25	% Gr. YoY	Q4 FY25	% Gr. QoQ
India Geography:	23,744	22,439	5.8%	24,475	-3.0%
<i>Formulations</i>	15,195	14,073	8.0%	15,394	-1.3%
<i>Consumer Wellness</i>	8,549	8,366	2.2%	9,081	-5.9%
US Formulations	31,817	30,929	2.9%	31,307	1.6%
International Mkt. Formulations	7,265	5,309	36.8%	5,547	31.0%
APIs	1,575	1,415	11.3%	1,290	22.1%
Alliances & Others	269	373	-27.9%	283	-4.9%
Consolidated Revenues	64,670	60,465	7.0%	62,902	2.8%



Our Q1 FY2026 performance reflects the results of our disciplined execution, with most of our key businesses meeting expectations. We remain firmly on track to achieve our FY2026 aspirations and are excited about the upcoming developments on the innovation front, which we believe will open up new avenues for sustainable growth. As we pursue these opportunities, we continue to keep the highest standards of compliance at the core of all our operations, while building strong future growth pillars that will strengthen our position globally.

Dr. Sharvil Patel, Managing Director - Zydus Lifesciences Limited

Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878



Q1 FY26 Business Updates

India Geography

- Comprises of Formulations and Consumer Wellness businesses and accounted for 37% of consolidated revenues.
- Registered revenues of Rs. 23,744 mn, up 6% YoY.

Formulations business

- Registered revenues of Rs. 15,195 mn, up 8% y-o-y. The business accounted for 24% of consolidated revenues.
- Branded formulations business grew faster than the market with 9% y-o-y growth driven by a strong uptick in pillar brands and innovation products.
- Chronic segment continued to grow at a faster pace driving the overall growth of the business.
- Outpaced the market growth in key therapies of Cardiology, Respiratory, Anti-infectives, Pain Management and in super specialty area of Oncology. Retained leadership position in the Oncology therapy.
- Share of chronic portfolio has increased consistently over the years and stood at 43.7%, which is an improvement of 420 bps over the last 3 years (Source: IQVIA MAT June 2025 data).

Consumer Wellness business

- Registered revenues of Rs. 8,549 mn, up 2% YoY. The business accounted for 13% of consolidated revenues.
- Excluding the seasonal brands, the business posted strong double-digit growth reflecting the underlying strength of the portfolio and balanced business model.
- Organized trade saliency continued to improve, reaching 30.9% in Q1 FY26, up from 23.3% in Q1 FY25. Within this, e-commerce contributed 14.5%, and modern trade contributed 16.4%.

Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878



US formulations business

- Registered revenues of Rs. 31,817 mn, up 3% YoY and 2% QoQ. The business accounted for 49% of consolidated revenues.
- In constant currency terms, the business registered revenues of US\$ 372 mn.
- Launched 3 new products during the quarter.
- Filed 3 ANDAs and received approval for 6 new products (including 2 tentative approvals) during the quarter.
- Expanding presence in specialty space by enriching 505(b)(2) portfolio and enhancing focus on pediatric rare diseases.

International Markets formulations business

- Registered revenues of Rs. 7,265 mn, up 37% YoY. The business accounted for 11% of consolidated revenues.
- Strong demand led growth was well spread across regions, benefitting from focused execution.

API business

- Registered revenues of Rs. 1,575 mn, up 11% YoY. The business accounted for 2% of consolidated revenues.

Alliances and Others

- Registered revenues of Rs. 269 mn, down 28% YoY. The business accounted for 0.4% of consolidated revenues.

Updates on Operations and Compliance

- API manufacturing facilities at Ankleshwar and Dabhasa received Establishment Inspection Reports (EIR) from the USFDA against the inspections conducted in March, 2025 and April, 2025 respectively.

Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878



Updates on Innovation Pipeline

NCE Research

- Initiated Phase II(b) clinical trials of Usnoflast, a novel oral NLRP3 inflammasome inhibitor, in the US, in patients with Amyotrophic Lateral Sclerosis (ALS).
- The USFDA granted Fast Track designation to the molecule for the ALS indication during the quarter. The molecule also holds an Orphan Drug Designation (ODD) from the USFDA for this indication.

Biotech R&D

- Received marketing authorization approval from the DCGI for Rituximab and Aflibercept biosimilars.
- Received regulatory approval to initiate Phase III clinical trials for the second antibody drug conjugate.

Vaccines R&D

- Completed Phase II clinical trials of Hepatitis E vaccine.
- Initiated Phase IV clinical trials of rabies vaccine to evaluate the long-term immunogenicity and safety viz-a-viz the WHO pre-qualified vaccine in animal bite cases.

Updates on Inorganic Initiatives

- Forayed into the global biologics CDMO business through the plan to acquire Agenus Inc.'s US based biologics manufacturing facilities. The acquisition marks the Company's strategic investment in the US based manufacturing for biologics, thereby adding a sustainable growth driver for the future.
- Successfully completed stake acquisition in Amplitude Surgical SA, France, a European MedTech leader in high-quality, lower-limb orthopedic technologies. Amplitude's portfolio comprises of technologically advanced products and solutions backed by cutting-edge research and innovation and complemented by robotic surgery system.

Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878



Q1 FY26 Earnings Call Details

The Company will host its post results' earnings call at **4:00 p.m. IST on 12th August, 2025** during which the leadership team will discuss the financial performance and address questions from the participants.

A transcript of the conference call will be available at the Company's website: <https://www.zyduslife.com/investorzone>

To join the call through Zoom:

Please pre-register by clicking here: <http://bit.ly/3Uih45Z>

About Zydus Lifesciences Limited

The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global life-sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 27000 people worldwide and is driven by its mission to unlock new possibilities in life-sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries. For more details visit www.zyduslife.com.

For further information, please contact -

Investors:

Mr. Arvind Bothra

Email: Arvind.bothra@zyduslife.com

Phone: +91-22-62711905

Media:

Ms. Sujatha Rajesh

Email: Sujatha.rajesh@zyduslife.com

Phone: +91-79-48040353

Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878

